Divi's Laboratories share news and announcements
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Last close ₹8,950.00down ₹212.00 (2.31%)BSE ₹8,984.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹9,162.00.
52-week range of traded prices to 23 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026
- Next results date: the board meets on 7 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,37,594 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 1 Aug 2026
- 81.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 14.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 1 Aug 2026
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 1 Aug 2026
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,20,26160.6% delivered
Divi's Laboratories share news and announcements
636 announcements, routine notices left out, newest first. Page 9 of 13.
Jul 2014
Jun 2014
23 Jun · Management
6 Jun · Updates
It has had an inspection by the US-FDA, with no major observations, for its Unit-II at vill. Chippada, Bheemunipatnam Mandal, near Visakhapatnam during June, 2014. The audit concluded with one observation primarily about further improvement of existing procedure. The purpose of this inspection was for Custom manufactured product.
May 2014
26 May · Dividend
Board of Directors of the Company at its meeting held on May 24, 2014 has recommended a dividend of 1000% i.e. Rs. 20/- per equity share of Rs. 2/- face value for the year ended March 31, 2014.5 May · Disclosure of Voting Pattern - Clause 35A
Apr 2014
Mar 2014
Feb 2014
Jan 2014
Nov 2013
Oct 2013
28 Oct · Board meeting
To consider and approve, inter-alia, the un-audited financial results for the half year and quarter ended September 30, 2013.
Aug 2013
6 Aug · Disclosure of Voting Pattern - Clause 35A
5 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2013
24 Jul · Board meeting
To consider and approve, inter-alia, the un-audited financial results for the first quarter ended June 30, 2013.1 Jul · Dividend
Dividend, when declared at the Annual General Meeting, will he credited / dispatched on August 19, 2013.
May 2013
21 May · Dividend
Board of Directors of the Company at its meeting held on May 20, 2013 has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013.20 May · Management
Prof. C. Ayyanna, Independent Director of the Company has resigned from the Board due to personal reasons and other pre-occupations. The Board has accepted his resignation and appreciated his contribution to the Company.11 May · Board meeting
Inter-alia, to consider and approve the audited financial results for the year ended March 31, 2013 and to recommend Dividend on Equity Shares for the year ended March 31, 2013, if any.
Feb 2013
Jan 2013
23 Jan · Board meeting
To consider and approve ,inter alia , the un-audited financial results for the third quarter ended December 31, 2012.
Nov 2012
5 Nov · Management
Board of Directors of the Company at its meeting held on November 03, 2012, has appointed Sri. Ranga Rao Ravipati as Additional Director (Independent and Non-Executive) on the Board of the Company w.e.f. November 03, 2012. Further, the Company has informed the Exchange that, Sri. G. Venkata Rao, Independent Director of the Company has resigned from the Board due to personal reasons and other pre-occupations. The Board has accepted his resignation and appreciated his contribution to the Company.
Oct 2012
19 Oct · Board meeting
To consider and approve, inter-alia, the un-audited financial results for the second quarter ended September 30, 2012.
Aug 2012
6 Aug · Disclosure of Voting Pattern - Clause 35A